Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지)

Korean Society of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회)
권호 표지
DOI QR코드

DOI QR Code

Bombesin-based Radiopharmaceuticals for Imaging and Therapy of Cancers Expressing Gastrin-releasing Peptide Receptor

  • Hwi-Soo Lim (Division of Applied RI, Korea Institute of Radiological & Medical Sciences, Radiological and Medico-Oncological Sciences, University of Science and Technology) ;
  • Choong Mo Kang (Division of Applied RI, Korea Institute of Radiological & Medical Sciences, Radiological and Medico-Oncological Sciences, University of Science and Technology)
  • Received : 2022.11.25
  • Accepted : 2022.12.08
  • Published : 2022.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Bombesin has a high binding affinity to gastrin-releasing peptide receptor (GRPR) and can be used as a targeting ligand in GRPR-related cancers. Because GRPR is overexpressed in prostate cancer, bombesin analogues have been investigated extensively for diagnosis and treatment of prostate cancer. In nuclear medicine, bombesin derivatives labeled with radiometals such as 55/57Co, 64Cu, 68Ga, 99mTc, and 177Lu or radiohalogen such as 131I and 211At were developed as markers for early detection of tumors and theragnostic tool for cancer treatment. This review focuses on the introduction of bombesin-based radiopharmaceuticals that are studied in pre-clinical or clinical research.

Keywords

Acknowledgement

This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No.2021-R1F1A1047996 and 50461-2022).

References

  1. Iagaru A, Will GRPR compete with PSMA as a target in prostate cancer? J Nucl Med 2017;58:1883-4. https://doi.org/10.2967/jnumed.117.198192
  2. Ohki-Hamazaki H, Iwabuchi M, Maekawa F. Development and function of bombesin-like peptides and their receptors. Int J DeV Biol 2005;49:293-300. https://doi.org/10.1387/ijdb.041954ho
  3. Battey JF, Way JM, Corjay MH, Shapira H, Kusano K, Harkins R, Wu JM, Slattery T, Mann E, Feldman RI. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc Natl Acad Sci USA1991;88(2):395-9. https://doi.org/10.1073/pnas.88.2.395
  4. Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R, Viallet J, Sausville EA, Battey JF. BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem 1993;268(8):5979-84. https://doi.org/10.1016/S0021-9258(18)53415-3
  5. Nagalla SR, Barry BJ, Creswick KC, Eden P, Taylor JT, Spindel ER. Cloning of a receptor for amphibian[Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: Identification of a fourth bombesin receptor subtype (BB4). Proc Natl Acad Sci USA 1995;92:6205-9. https://doi.org/10.1073/pnas.92.13.6205
  6. Wada E, Way J, Shapira H, Kusano K, Lebacq-Verheyden AM, Coy D, Jensen R, Battey J. cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor. Neuron1991;6:421-0.
  7. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, Reubi JC. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008;49(2):318-26. https://doi.org/10.2967/jnumed.107.045054
  8. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24(4): 389-427. https://doi.org/10.1210/er.2002-0007
  9. Llinares M, Devin C, Chaloin O, Azay J, Noel-Artis AM, Bernad N, Fehrentz JA, Martinez J. Syntheses and biological activities of potent bombesin receptor antagonists. J Pept Res 1999;53(3):275-83. https://doi.org/10.1034/j.1399-3011.1999.00028.x
  10. Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, Welch MJ. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjugate Chem. 2003;14:756-63. https://doi.org/10.1021/bc034018l
  11. Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat 2006;101(2):175-83. https://doi.org/10.1007/s10549-006-9287-8
  12. Kim MH, Park JA, Woo SK, Lee KC, An GI, Kim BS, Kim KI, Lee TS, Kim CW, Kim KM, Kang JH, Lee YJ. Evaluation of a 64Cu-labeled 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA)-galactose-bombesin analogue as a PET imaging probe in a gastrin-releasing peptide receptor-expressing prostate cancer xenograft model. Int j Oncol 2015;46(3):1159-68. https://doi.org/10.3892/ijo.2015.2832
  13. Escudero-Castellanos A, Ocampo-Garcia B, Ferro-Flores G, Santos-Cuevas C, Morales-Avila E, Luna-Gutierrez M, Isaac-Olive K. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer. Nucl Med Commun 2018;40(3):278-86.
  14. Kahkonen E, Jambor I, Kemppainen J, Lehtio K, Gronroos TJ, Kuisma A, Luoto P, Sipila HJ, Tolvanen T, Alanen K, Silen J, Kallajoki M, Roivainen A, Schafer N, Schibli R, Dragic M, Johayem A, Valencia R, Borkowski S, Minn H. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res 2013;19(19):5434-43. https://doi.org/10.1158/1078-0432.CCR-12-3490
  15. Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist - from mice to men. Theranostics 2014;4(4):412-9. https://doi.org/10.7150/thno.7324
  16. Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP. Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results. J Nucl Med 2017;58(1):75-80. https://doi.org/10.2967/jnumed.116.178889
  17. Sah BR, Burger IA, Schibli R, Friebe M, Dinkelborg L, Graham K, Borkowski S, Bacher-Stier C, Valencia R, Srinivasan A, Hany TF, Mu L, Wild PJ, Schaefer NG. Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer. J Nucl Med 2015;56(3):372-8. https://doi.org/10.2967/jnumed.114.147116
  18. Budaus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C. Initial experience of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 2016;69(3):393-6. https://doi.org/10.1016/j.eururo.2015.06.010
  19. Rivera-Bravo B, Ramirez-Nava G, Mendoza-Figueroa MJ, Ocampo-Garcia B, Ferro-Flores G, Avila-Rodriguez MA, Santos-Cuevas C. [68Ga]Ga-iPSMA-Lys3-Bombesin: Biokinetics, dosimetry and first patient PET/CT imaging.Nucl Med Biol 2021;96-97(54-60):54-60. https://doi.org/10.1016/j.nucmedbio.2021.03.005
  20. Roivainen A, Kahkonen E, Luoto P, Borkowski S, Hofmann B, Jambor I, Lehtio K, Rantala T, Rottmann A, Sipila H, Sparks R, Suilamo S, Tolvanen T, Valencia R, Minn H. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY86-7548 in healthy men. J Nucl Med 2013;54(6):867-72. https://doi.org/10.2967/jnumed.112.114082
  21. Manrique-Arias JC, Pitalua-Cortes Q, Pedrero-Piedras R, Rodriguez-Mena G, Lopez T, Cabezas-Ortiz C, Garcia-Perez O. Synthesis and radiation dosimetry of [68Ga]-Ga-Lys1,Lys3-DOTA-bombesin (1,14) antagonist for PET-imaging, as a potential theragnostic tracer in oncology. J Encap Adsor Sci 2020;10:29-41.
  22. Choi YJ, Jeong YH, Kim HJ, Lee JH, Cho A, Yun M, Lee JD, Kang WJ. Correlation between hormonal receptor status/human epidermal growth factor receptor 2 overexpression and 18F-FDG uptake in patients with breast cancer. J Nucl Med 2012;53(Suppl 1):1285.
  23. Yoon HJ, Kang KW, Chun IK, Cho N, Im SA, Jeong S, Lee S, Jung KC, Lee YS, Jeong JM, Lee DS, Chung JK, Moon WK. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2014;41(8):1534-43. https://doi.org/10.1007/s00259-014-2744-4
  24. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: A potentially useful method for disease characterization. Cancer 2008;112(5):995-1000. https://doi.org/10.1002/cncr.23226
  25. Morgat C, MacGrogan G, Brouste V, Velasco V, Sevenet N, Bonnefoi H, Fernandez P, Debled M, Hindie E. Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: A study of 1,432 primary tumors. J Nucl Med 2017;58(9):1401-7. https://doi.org/10.2967/jnumed.116.188011
  26. Wong K, Sheehan-Dare G, Nguyen A, Ho B, Liu V, Lee J, Brown L, Dear R, Chan L, Sharma S, Malaroda A, Smith I, Lim E, Emmett L. 64Cu-SAR-bombesin PET-CT imaging in the staging of estrogen/progesterone receptor positive, HER2 negative metastatic breast cancer patients: Safety, dosimetry and feasibility in a Phase I Trial. Pharmaceuticals 2022;15(7):772.
  27. Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, Drake CG, de Bono JS, Prostate cancer. Lancet 2016;387(10013):70-82. https://doi.org/10.1016/S0140-6736(14)61947-4
  28. Kelly SP, Anderson WF, Rosenberg PS, Cook MB, Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus 2018;4(1):121-7. https://doi.org/10.1016/j.euf.2017.10.014
  29. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23. https://doi.org/10.1056/NEJMoa1213755
  30. Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A, 225Ac-PSMA-617 for PSMA targeting α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med 2016;57(12):1941-4. https://doi.org/10.2967/jnumed.116.178673
  31. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy Curr Pharm Des 2000;6:1433-55. https://doi.org/10.2174/1381612003399275
  32. Vaidyanathan G, Zalutsky MR. Astatine radiopharmaceuticals: prospects and problems. Curr Radiopharm 2008;1(3):177-96. https://doi.org/10.2174/1874471010801030177
  33. Guerard F, Gestin JF, Brechbiel MW, Production of [211At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy. Cancer Biother Radiopharm 2013;28(1):1-20.
  34. Aoki M, Zhao S, Takahashi K, Washiyama K, Ukon N, Tan C, Shimoyama S, Nishijima KI, Ogawa K, Preliminary evaluation of astatine-211-labeled bombesin derivatives for targeted alpha therapy. Chem Pharm Bull 2020;68(6):538-45. https://doi.org/10.1248/cpb.c20-00077
  35. Garg PK, Harrison CL, Zalutsky MR. Comparative tissue distribution in mice of the α-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 Fragment. Cancer Res 1990;50:3514-20.
  36. Wilbur DS, Hamlin DK, Chyan MK, Kegley BB, Quinn J, Vessella RL, Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives. Bioconjug Chem 2004;15:601-16. https://doi.org/10.1021/bc034229q
  37. Barve A, Jin W, Cheng K. Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release 2014;187:118-32. https://doi.org/10.1016/j.jconrel.2014.05.035
  38. de Visser M, van Weerden WM, de Ridder CMA, Reneman S, Melis M, Krenning EP, de Jong M. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. J Nucl Med 2007;48(1):88-93.
  39. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3(1):81-5.
  40. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52(4):637-40. https://doi.org/10.1016/S0090-4295(98)00278-7
  41. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001;22(4):248-91. https://doi.org/10.1006/frne.2001.0217
  42. Abouzayed A, Yim CB, Mitran B, Rinne SS, Tolmachev V, Larhed M, Rosenstrom U, Orlova A. Synthesis and preclinical evaluation of radio-iodinated GRPR/PSMA bispecific heterodimers for the theranostics application in prostate cancer. Pharmaceutics 2019;11(7):358.